BR0016150A - Compostos, composições e métodos para estìmulo de crescimento e alongamento neuronal - Google Patents
Compostos, composições e métodos para estìmulo de crescimento e alongamento neuronalInfo
- Publication number
- BR0016150A BR0016150A BR0016150-0A BR0016150A BR0016150A BR 0016150 A BR0016150 A BR 0016150A BR 0016150 A BR0016150 A BR 0016150A BR 0016150 A BR0016150 A BR 0016150A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- methods
- compositions
- stimulating growth
- stimulating
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 230000004936 stimulating effect Effects 0.000 title abstract 3
- 230000001537 neural effect Effects 0.000 title 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 101710103508 FK506-binding protein Proteins 0.000 abstract 1
- 101710104425 FK506-binding protein 2 Proteins 0.000 abstract 1
- 101710104423 FK506-binding protein 3 Proteins 0.000 abstract 1
- 101710104333 FK506-binding protein 4 Proteins 0.000 abstract 1
- 101710104342 FK506-binding protein 5 Proteins 0.000 abstract 1
- 101710149710 FKBP-type 16 kDa peptidyl-prolyl cis-trans isomerase Proteins 0.000 abstract 1
- 101710121306 FKBP-type 22 kDa peptidyl-prolyl cis-trans isomerase Proteins 0.000 abstract 1
- 101710180800 FKBP-type peptidyl-prolyl cis-trans isomerase FkpA Proteins 0.000 abstract 1
- 101710104030 Long-type peptidyl-prolyl cis-trans isomerase Proteins 0.000 abstract 1
- 101710114693 Outer membrane protein MIP Proteins 0.000 abstract 1
- 101710116692 Peptidyl-prolyl cis-trans isomerase Proteins 0.000 abstract 1
- 101710111764 Peptidyl-prolyl cis-trans isomerase FKBP10 Proteins 0.000 abstract 1
- 101710111749 Peptidyl-prolyl cis-trans isomerase FKBP11 Proteins 0.000 abstract 1
- 101710111747 Peptidyl-prolyl cis-trans isomerase FKBP12 Proteins 0.000 abstract 1
- 101710111757 Peptidyl-prolyl cis-trans isomerase FKBP14 Proteins 0.000 abstract 1
- 101710111682 Peptidyl-prolyl cis-trans isomerase FKBP1A Proteins 0.000 abstract 1
- 101710111689 Peptidyl-prolyl cis-trans isomerase FKBP1B Proteins 0.000 abstract 1
- 101710147154 Peptidyl-prolyl cis-trans isomerase FKBP2 Proteins 0.000 abstract 1
- 101710147149 Peptidyl-prolyl cis-trans isomerase FKBP3 Proteins 0.000 abstract 1
- 101710147152 Peptidyl-prolyl cis-trans isomerase FKBP4 Proteins 0.000 abstract 1
- 102100020739 Peptidyl-prolyl cis-trans isomerase FKBP4 Human genes 0.000 abstract 1
- 101710147150 Peptidyl-prolyl cis-trans isomerase FKBP5 Proteins 0.000 abstract 1
- 101710147138 Peptidyl-prolyl cis-trans isomerase FKBP7 Proteins 0.000 abstract 1
- 101710147137 Peptidyl-prolyl cis-trans isomerase FKBP8 Proteins 0.000 abstract 1
- 101710147136 Peptidyl-prolyl cis-trans isomerase FKBP9 Proteins 0.000 abstract 1
- 101710174853 Peptidyl-prolyl cis-trans isomerase Mip Proteins 0.000 abstract 1
- 101710200991 Peptidyl-prolyl cis-trans isomerase, rhodopsin-specific isozyme Proteins 0.000 abstract 1
- 101710092145 Peptidyl-prolyl cis-trans isomerase-like 1 Proteins 0.000 abstract 1
- 101710092146 Peptidyl-prolyl cis-trans isomerase-like 2 Proteins 0.000 abstract 1
- 101710092148 Peptidyl-prolyl cis-trans isomerase-like 3 Proteins 0.000 abstract 1
- 101710092149 Peptidyl-prolyl cis-trans isomerase-like 4 Proteins 0.000 abstract 1
- 101710113444 Probable parvulin-type peptidyl-prolyl cis-trans isomerase Proteins 0.000 abstract 1
- 101710090737 Probable peptidyl-prolyl cis-trans isomerase Proteins 0.000 abstract 1
- 101710133309 Putative peptidyl-prolyl cis-trans isomerase Proteins 0.000 abstract 1
- 101710124237 Short-type peptidyl-prolyl cis-trans isomerase Proteins 0.000 abstract 1
- 102000023732 binding proteins Human genes 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000005036 nerve Anatomy 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 230000014511 neuron projection development Effects 0.000 abstract 1
- 230000007514 neuronal growth Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000008929 regeneration Effects 0.000 abstract 1
- 238000011069 regeneration method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16824699P | 1999-12-01 | 1999-12-01 | |
| PCT/US2000/032679 WO2001040185A1 (en) | 1999-12-01 | 2000-12-01 | Compounds, compositions, and methods for stimulating neuronal growth and elongation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0016150A true BR0016150A (pt) | 2002-08-13 |
Family
ID=22610717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0016150-0A BR0016150A (pt) | 1999-12-01 | 2000-12-01 | Compostos, composições e métodos para estìmulo de crescimento e alongamento neuronal |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6544987B2 (enExample) |
| EP (1) | EP1237869A1 (enExample) |
| JP (1) | JP2004500355A (enExample) |
| AR (1) | AR029411A1 (enExample) |
| AU (1) | AU1810001A (enExample) |
| BR (1) | BR0016150A (enExample) |
| CA (1) | CA2389368A1 (enExample) |
| CO (1) | CO5261615A1 (enExample) |
| DO (1) | DOP2000000107A (enExample) |
| GT (1) | GT200000203A (enExample) |
| HK (1) | HK1048987A1 (enExample) |
| HN (1) | HN2000000268A (enExample) |
| MX (1) | MXPA02005510A (enExample) |
| PA (1) | PA8508001A1 (enExample) |
| PE (1) | PE20011101A1 (enExample) |
| SV (1) | SV2002000233A (enExample) |
| UY (1) | UY26464A1 (enExample) |
| WO (1) | WO2001040185A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7405234B2 (en) * | 2002-05-17 | 2008-07-29 | Bristol-Myers Squibb Company | Bicyclic modulators of androgen receptor function |
| EP1567487A4 (en) | 2002-11-15 | 2005-11-16 | Bristol Myers Squibb Co | OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION |
| US7820702B2 (en) * | 2004-02-04 | 2010-10-26 | Bristol-Myers Squibb Company | Sulfonylpyrrolidine modulators of androgen receptor function and method |
| US7388027B2 (en) * | 2004-03-04 | 2008-06-17 | Bristol-Myers Squibb Company | Bicyclic compounds as modulators of androgen receptor function and method |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| PT1773816E (pt) * | 2004-06-24 | 2015-04-29 | Vertex Pharma | Moduladores de transportadores de cassete de ligação de atp |
| US7544171B2 (en) * | 2004-10-22 | 2009-06-09 | General Patent Llc | Methods for promoting nerve regeneration and neuronal growth and elongation |
| US7988648B2 (en) * | 2005-03-04 | 2011-08-02 | General Patent, Llc | Pancreas regeneration treatment for diabetics using extracorporeal acoustic shock waves |
| WO2006106423A2 (en) * | 2005-04-07 | 2006-10-12 | Pfizer Inc. | Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase |
| JO2722B1 (en) | 2005-09-09 | 2013-09-15 | سميث كلاين بيتشام كوربوريشن | New vehicles |
| US7419394B2 (en) * | 2005-11-11 | 2008-09-02 | Rockwell Automation Technologies, Inc. | Electrical system having withdrawable unit with maintained control and communication connection |
| EP1979367A2 (en) * | 2005-12-24 | 2008-10-15 | Vertex Pharmaceuticals Incorporated | Quinolin-4-one derivatives as modulators of abc transporters |
| RS55940B1 (sr) | 2005-12-28 | 2017-09-29 | Vertex Pharma | Čvrsti oblici n-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksohinolin-3-karboksamida |
| CN101569864B (zh) * | 2008-04-29 | 2011-08-03 | 中山大学 | 手性磺胺类有机小分子催化剂及其应用 |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| EP2821400B1 (en) | 2009-03-20 | 2017-09-27 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| MX2014010253A (es) | 2012-02-27 | 2014-11-12 | Vertex Pharma | Composicion farmaceutica y administraciones de la misma. |
| RU2749213C2 (ru) | 2014-10-07 | 2021-06-07 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе |
| US11389371B2 (en) | 2018-05-21 | 2022-07-19 | Softwave Tissue Regeneration Technologies, Llc | Acoustic shock wave therapeutic methods |
| US11389373B2 (en) | 2016-04-18 | 2022-07-19 | Softwave Tissue Regeneration Technologies, Llc | Acoustic shock wave therapeutic methods to prevent or treat opioid addiction |
| US11458069B2 (en) | 2016-04-18 | 2022-10-04 | Softwave Tissue Regeneration Technologies, Llc | Acoustic shock wave therapeutic methods to treat medical conditions using reflexology zones |
| US11389372B2 (en) | 2016-04-18 | 2022-07-19 | Softwave Tissue Regeneration Technologies, Llc | Acoustic shock wave therapeutic methods |
| US11389370B2 (en) | 2016-04-18 | 2022-07-19 | Softwave Tissue Regeneration Technologies, Llc | Treatments for blood sugar levels and muscle tissue optimization using extracorporeal acoustic shock waves |
| US11345659B2 (en) * | 2018-01-30 | 2022-05-31 | Board Of Regents, The University Of Texas System | Pipecolic esters for inhibition of the proteasome |
| US20240327392A1 (en) * | 2021-06-25 | 2024-10-03 | Albius Sciences Alpha Private Limited | Heterocycloalkyl-substituted polyheteroazole derivatives as medicaments for treating and/or preventing rs virus infections |
| US12402898B2 (en) | 2023-01-27 | 2025-09-02 | Softwave Tissue Regeneration Technologies, Llc | Acoustic shock wave or pressure pulse treatment for proptosis or exophthalmos |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3587308T2 (de) | 1984-12-20 | 1993-08-19 | Upjohn Co | Monobactame. |
| US5192773A (en) | 1990-07-02 | 1993-03-09 | Vertex Pharmaceuticals, Inc. | Immunosuppressive compounds |
| US5244905A (en) | 1990-08-31 | 1993-09-14 | Warner-Lambert Company | N-substituted cycloalkyl and polycycloalkyl polyhydro-β-carboline-phenylalanine- and phenethylamine derivatives |
| US5219851A (en) | 1991-03-05 | 1993-06-15 | Warner-Lambert Company | Tetrahydroisoquinoline-type renin inhibiting peptides |
| DE4141218A1 (de) | 1991-12-13 | 1993-06-17 | Luitpold Werk Chem Pharm | Thiadiazincarbonsaeureamidderivate, verfahren zu ihrer herstellung und arzneimittel |
| DE4217719A1 (de) | 1992-05-29 | 1993-12-02 | Bayer Ag | Zweifach heterocyclisch substituierte Sulfonylamino(thio)carbonylverbindungen |
| US5798355A (en) | 1995-06-07 | 1998-08-25 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity |
| US5612350A (en) | 1993-11-30 | 1997-03-18 | Abbott Laboratories | Macrocyclic immunomodulators with novel cyclohexyl ring replacements |
| US5494925A (en) | 1994-12-02 | 1996-02-27 | Sterling Winthrop Inc. | 2-heterocyclyloxymethyl and 2-heterocyclylthiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof |
| US5541168A (en) | 1994-12-02 | 1996-07-30 | Sterling Winthrop Inc. | Substituted 2-(phosphinyloxymethyl)-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof |
| US5556909A (en) | 1994-12-02 | 1996-09-17 | Sanofi Winthrop Inc. | Substituted 2-arylcarbonyloxymethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxide derivatives and compositions and method of use thereof |
| US5614547A (en) | 1995-06-07 | 1997-03-25 | Guilford Pharmaceuticals Inc. | Small molecule inhibitors of rotamase enzyme |
| US5859031A (en) | 1995-06-07 | 1999-01-12 | Gpi Nil Holdings, Inc. | Small molecule inhibitors of rotamase enzyme activity |
| US5696135A (en) | 1995-06-07 | 1997-12-09 | Gpi Nil Holdings, Inc. | Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth |
| US6037370A (en) | 1995-06-08 | 2000-03-14 | Vertex Pharmaceuticals Incorporated | Methods and compositions for stimulating neurite growth |
| GB9521322D0 (en) | 1995-10-17 | 1995-12-20 | Sandoz Ltd | Organic compounds |
| US5801197A (en) | 1995-10-31 | 1998-09-01 | Gpi Nil Holdings, Inc. | Rotamase enzyme activity inhibitors |
| DE19542189A1 (de) | 1995-11-13 | 1997-05-15 | Hoechst Ag | Cyclische N-substituierte alpha-Iminohydroxamsäuren |
| PL186869B1 (pl) | 1995-11-13 | 2004-03-31 | Hoechst Ag | Nowe heterocykliczne N-podstawione pochodne kwasów alfa-iminohydroksamowych i karboksylowych, sposób ich wytwarzania, środek farmaceutyczny i ich zastosowanie |
| US5801187A (en) | 1996-09-25 | 1998-09-01 | Gpi-Nil Holdings, Inc. | Heterocyclic esters and amides |
| US5786378A (en) | 1996-09-25 | 1998-07-28 | Gpi Nil Holdings, Inc. | Heterocyclic thioesters |
| US5935989A (en) | 1996-12-31 | 1999-08-10 | Gpi Nil Holdings Inc. | N-linked ureas and carbamates of heterocyclic thioesters |
| US5874449A (en) * | 1996-12-31 | 1999-02-23 | Gpi Nil Holdings, Inc. | N-linked sulfonamides of heterocyclic thioesters |
| WO1998032748A1 (en) | 1997-01-23 | 1998-07-30 | F. Hoffmann-La Roche Ag | Sulfamide-metalloprotease inhibitors |
| US5721256A (en) | 1997-02-12 | 1998-02-24 | Gpi Nil Holdings, Inc. | Method of using neurotrophic sulfonamide compounds |
| ZA98825B (en) | 1997-02-27 | 1998-10-19 | Guilford Pharm Inc | Method of using neurotrophic carbamates and ureas |
| US5846979A (en) | 1997-02-28 | 1998-12-08 | Gpi Nil Holdings, Inc. | N-oxides of heterocyclic esters, amides, thioesters, and ketones |
| GB9804426D0 (en) | 1998-03-02 | 1998-04-29 | Pfizer Ltd | Heterocycles |
| US6121280A (en) * | 1998-03-24 | 2000-09-19 | Pfizer Inc. | Azabicyclic rotomase inhibitors |
| JP2002516857A (ja) | 1998-06-02 | 2002-06-11 | ブリストルーマイヤーズ スクイブ カンパニー | 神経栄養性ジフルオロアミド剤 |
| US6331537B1 (en) | 1998-06-03 | 2001-12-18 | Gpi Nil Holdings, Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds |
| PL346011A1 (en) | 1998-07-21 | 2002-01-14 | Warner Lambert Co | Coadministration of acat and mmp inhibitors for the treatment of atherosclerotic lesions |
| GB9815880D0 (en) | 1998-07-21 | 1998-09-16 | Pfizer Ltd | Heterocycles |
| HUP0300719A2 (hu) | 1998-09-18 | 2003-11-28 | Amgen, Inc. | Áthidalt heterociklusos vegyületek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk |
| AU3221300A (en) | 1999-02-03 | 2000-08-25 | Schering Aktiengesellschaft | Carboxylic acid derivatives, process for their preparation and their use as rotamase enzyme activity inhibitors |
-
2000
- 2000-11-30 DO DO2000000107A patent/DOP2000000107A/es unknown
- 2000-11-30 GT GT200000203A patent/GT200000203A/es unknown
- 2000-11-30 CO CO00091748A patent/CO5261615A1/es not_active Application Discontinuation
- 2000-12-01 EP EP00980901A patent/EP1237869A1/en not_active Withdrawn
- 2000-12-01 WO PCT/US2000/032679 patent/WO2001040185A1/en not_active Ceased
- 2000-12-01 HN HN2000000268A patent/HN2000000268A/es unknown
- 2000-12-01 PE PE2000001288A patent/PE20011101A1/es not_active Application Discontinuation
- 2000-12-01 CA CA002389368A patent/CA2389368A1/en not_active Abandoned
- 2000-12-01 SV SV2000000233A patent/SV2002000233A/es unknown
- 2000-12-01 US US09/726,314 patent/US6544987B2/en not_active Expired - Fee Related
- 2000-12-01 AR ARP000106371A patent/AR029411A1/es not_active Application Discontinuation
- 2000-12-01 UY UY26464A patent/UY26464A1/es not_active Application Discontinuation
- 2000-12-01 AU AU18100/01A patent/AU1810001A/en not_active Abandoned
- 2000-12-01 PA PA20008508001A patent/PA8508001A1/es unknown
- 2000-12-01 BR BR0016150-0A patent/BR0016150A/pt not_active Application Discontinuation
- 2000-12-01 MX MXPA02005510A patent/MXPA02005510A/es active IP Right Grant
- 2000-12-01 JP JP2001541871A patent/JP2004500355A/ja not_active Abandoned
- 2000-12-01 HK HK03100726.8A patent/HK1048987A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU1810001A (en) | 2001-06-12 |
| AR029411A1 (es) | 2003-06-25 |
| WO2001040185B1 (en) | 2001-11-15 |
| SV2002000233A (es) | 2002-12-02 |
| US20020061881A1 (en) | 2002-05-23 |
| PE20011101A1 (es) | 2001-11-29 |
| PA8508001A1 (es) | 2002-08-26 |
| US6544987B2 (en) | 2003-04-08 |
| WO2001040185A1 (en) | 2001-06-07 |
| EP1237869A1 (en) | 2002-09-11 |
| UY26464A1 (es) | 2001-07-31 |
| GT200000203A (es) | 2002-05-24 |
| HN2000000268A (es) | 2003-12-11 |
| CO5261615A1 (es) | 2003-03-31 |
| MXPA02005510A (es) | 2004-09-10 |
| DOP2000000107A (es) | 2002-09-16 |
| CA2389368A1 (en) | 2001-06-07 |
| HK1048987A1 (zh) | 2003-04-25 |
| JP2004500355A (ja) | 2004-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0016150A (pt) | Compostos, composições e métodos para estìmulo de crescimento e alongamento neuronal | |
| FI942075A0 (fi) | Sappihappojohdannaisten tetratsolijohdannaisia, menetelmä niiden valmistamiseksi ja näiden yhdisteiden käyttö lääkeaineina | |
| TW289020B (enExample) | ||
| DK0831812T3 (da) | Fremgangsmåder og præparater til stimulering af neuritvækst | |
| SV1999000102A (es) | Compuestos heterociclicos como inhibidores de enzimas de rotamasa. ref. pcs 9475 afae/bb. | |
| BR0116216A (pt) | Inibidores de girase e seus usos | |
| BR9811685A (pt) | Derivados de piridina | |
| DE59903921D1 (de) | Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen | |
| BR0007527A (pt) | Fenilfenantridinas com atividade inibitória depde-iv | |
| BR9713465A (pt) | Inibidores metalotprotease de amina cìclica sibstituìda | |
| BRPI0417260A (pt) | derivados de azepinoindol como agentes farmacêuticos | |
| TR200000482T2 (tr) | N-Aroilfenilalanin türevleri. | |
| BR0010716A (pt) | Compostos de fenila substituìdos com atividade imunossupressora e composições farmacêuticas | |
| DE69429524D1 (de) | Aminocyclohexylester und ihre anwendung | |
| DE69627035D1 (de) | Derivate von aminosäuren, sie enthaltende pharmazeutische zusammensetzungen sowie deren herstellunsgverfahren | |
| BR0109062A (pt) | Inibidores de frutose-1,6-bisfosfatase de arila | |
| BR9508074A (pt) | Composto e processo de regulagem de meiose em uma célula- embrião de mamífero | |
| BR9811923A (pt) | Compostos possuindo atividade neuronal | |
| BR9907746A (pt) | ácidos 2,3,4,5-tetraidro-1h[1,4]-benzodiazepina-3-hidroxâmic os como inibidores de matriz de metaloproteinase | |
| BRPI0416030A (pt) | pirido-7-pirimidin-7-onas substituìdas com hidroxialquila | |
| ATE420101T1 (de) | Isolierung von nervenstammzellen unter verwendung von gangliosiden und anderen oberflächenmarkern | |
| BR9814188A (pt) | "agonistas de 5-ht1f" | |
| AP2000001937A0 (en) | Method for identifying chemical active agents and active agents for inhibiting the 1-desoxy-d-xylulose-5-phosphate biosynthetic pathway. | |
| ATE223214T1 (de) | Von milchsäure abgeleitete butyrat-prodrugs | |
| DK0863866T3 (da) | Butyrat-prodrugs afledt af mælkesyre |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10, 13 E 25 DA LPI |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |